Moderna said its Covid-19 booster vaccine, targeting the BA.1 sub-variant of Omicron, produced a high immune response, lasting at least 3 months.

Moderna chief executive Stephane Bancel said: “Clinical trial data now indicate that the body of people receiving booster shots from Pfizer and Moderna produces a superior immune response in at least three years. month”.

Both the new vaccines from Pfizer and Moderna are “bivalent ” vaccines , because they not only target the original SARS-CoV-2 virus strain but also the Omicron variant.

Vaccines from Pfizer and Moderna developed against the Omicron variant have been licensed in several countries.

The United States is the first country to license the booster vaccine targeting the BA.4 and BA.5 sub-variants of Omicron. The US government has bought 175 million booster doses of the vaccine in an effort to prevent a new wave of infections as schools reopen and people will be in more enclosed spaces as winter approaches.

Meanwhile, Moderna is currently awaiting data from human clinical trials of vaccines targeting sub-variants BA.4 and BA.5 later this year.

Moderna’s vaccine is licensed for people 18 years of age and older, while Pfizer’s is licensed for people 12 years and older.

Previous generation vaccines can still prevent severe complications from Covid-19, but their ability to fight infection is low in the face of more and more new strains. This new generation of vaccines is expected to effectively prevent the transmission of Omicron sub-lines, in addition to preventing the disease from becoming severe.–Og–Og?language=php

By Jaya